Merck stock (US58933Y1055): Q1 earnings beat, revenue guidance narrowed

Merck reported first-quarter 2026 earnings on April 30, beating EPS estimates while raising full-year revenue guidance slightly below consensus, signaling mixed momentum for the pharma giant.

Merck & Co. announced Q1 2026 earnings on April 30, 2026, delivering an earnings per share of negative $1.28, which beat the consensus estimate of negative $1.47 by $0.19, according to MarketBeat as of May 11, 2026. Quarterly revenue rose 4.9% year-over-year to $16.29 billion, exceeding analyst estimates of $15.85 billion. The company issued full-year revenue guidance of $65.8 billion to $67.0 billion, compared to the consensus revenue estimate of $66.5 billion, placing the midpoint slightly below market expectations.

As of: May 11, 2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Merck & Co., Inc.
• Sector/industry: Pharmaceuticals
• Headquarters/country: United States
• Core markets: Global pharmaceutical and healthcare
• Key revenue drivers: Prescription pharmaceuticals, vaccines, oncology
• Home exchange/listing venue: NYSE (MRK)
• Trading currency: USD

Merck & Co.: core business model

Merck & Co. operates as a diversified global pharmaceutical company with a portfolio spanning prescription medications, vaccines, and oncology treatments. The company serves healthcare systems, hospitals, and patients across developed and emerging markets. Revenue generation relies on both established branded drugs and newer therapeutic launches, with significant exposure to chronic disease management and preventive care segments that serve the aging US population.

Main revenue and product drivers for Merck

The company's revenue growth in Q1 2026 was supported by continued demand for its core therapeutic areas. The 4.9% year-over-year revenue increase to $16.29 billion reflects contributions from both legacy products and newer launches. Merck's diversified portfolio reduces dependence on any single drug, though patent expirations and generic competition remain ongoing headwinds. The full-year guidance of $65.8 billion to $67.0 billion suggests management expects mid-single-digit growth, with the midpoint implying approximately 4.8% growth at the $66.4 billion midpoint versus prior-year expectations.

Earnings performance and forward guidance

The negative EPS in Q1 reflects typical pharmaceutical accounting patterns, including one-time charges and R&D investments. Trailing EPS stands at $3.55 over the last four quarters, with net income recorded at $18.25 billion. Analysts project earnings growth of 89.34% next year, from $5.16 to $9.77 per share, suggesting a significant earnings inflection expected in coming periods. This projection reflects anticipated contributions from pipeline advancement and operational leverage. The stock traded at $111.26 USD on May 8, 2026, on the NYSE, according to MarketBeat as of May 11, 2026.

Conclusion

Merck's Q1 2026 results demonstrate solid operational execution with revenue beating estimates and EPS topping consensus expectations. The full-year guidance, while slightly below consensus midpoint, reflects management's cautious stance amid ongoing patent cliff pressures and competitive dynamics in global pharmaceuticals. For US investors, Merck remains a core holding in diversified healthcare portfolios, with the projected 89% earnings growth next year suggesting potential upside if the company executes on pipeline and operational initiatives. The stock's valuation at a P/E ratio of 31.34 reflects elevated growth expectations that will require sustained execution to justify.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.